Abstract:The ability of cancers to evade immune surveillance and resist immunotherapy raises a fundamental question of how tumor cells survive in the presence of a competent immune system. Studies to address this question have primarily focused on mechanisms by which tumor cells avoid recognition by or induce tolerance in the immune system. However, little is known about whether cancer cells also acquire an intrinsic ability to resist killing by immune effectors. We find that cancer cells enhance their ability to withstand an attack by cytotoxic immune effector cells via acquisition of specific genetic alterations that interfere with the shared mitochondrial death signaling pathway entrained by granzyme B, IFN-gamma, and Apo2 ligand/tumor necrosis factor-related apoptosis inducing ligand (Apo2L/TRAIL), three key mediators of immunologic cell-mediated cytotoxicity. We show that the coexistence of specific mitochondrial signaling defects (either deletion of Bax, overexpression of Bcl-x(L), or deletion of Smac) with expression of X-linked inhibitor of apoptosis protein decreases the sensitivity of cancer cells to IFN-gamma/Apo2L/TRAIL- or granzyme B-induced apoptosis, lymphocyte-mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo. Conversely, negating X-linked inhibitor of apoptosis protein expression or function in tumor cells with defective mitochondrial signaling enables direct activation of caspase-3/-7 by granzyme B or Apo2L/TRAIL, and restores their susceptibility to immunologic cytotoxicity. These findings identify an important mechanism by which cancers evade elimination by immune effector cells and suggest that cancer immunotherapy might be improved by concurrent strategies to alleviate or circumvent the intrinsic mitochondrial death signaling defects that help cancer cells resist immunologic cytotoxicity.

Manipulating mitochondrial electron flow enhances tumor immunogenicity

Tumour immunogenicity goes with the (mitochondrial electron) flow

Research Progress on Mitochondria Regulating Tumor Immunity.

Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma

Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy

Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Mitochondrial Immune Regulation and Anti-Tumor Immunotherapy Strategies Targeting Mitochondria

Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8 + T cell metabolic fitness and function in tumors

Inhibition of Mitochondrial Fission Reverses the Immunoescape of Solid Tumors via IRE1α-XBP-1s-TPP2 axis

Resistance Of Cancers To Immunologic Cytotoxicity And Adoptive Immunotherapy Via X-Linked Inhibitor Of Apoptosis Protein Expression And Coexisting Defects In Mitochondrial Death Signaling

Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies

Mitochondrial ETF insufficiency drives neoplastic growth by selectively optimizing cancer bioenergetics

Mitochondrial metabolism sustains CD8 T cell migration for an efficient infiltration into solid tumors

Mitochondrial metabolism sustains CD8+ T cell migration for an efficient infiltration into solid tumors

Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells

Endothelial Mitochondria Transfer to Melanoma Induces M2-Type Macrophage Polarization and Promotes Tumor Growth by the Nrf2/HO-1-Mediated Pathway

Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis

Immunometabolic characteristics of Dendritic Cells and its significant modulation by mitochondria-associated signaling in the tumor microenvironment influence cancer progression